Verrica Pharmaceuticals (VRCA) 25th Annual Needham Virtual Healthcare Conference summary

Company overview and commercial strategy

• YCANTH is approved for molluscum contagiosum and actively commercialized in the US and Japan, with expansion into common warts underway and a fully funded Phase III program supported by a Japanese partner.

• Revenue and applicator unit growth nearly doubled in the past year, driven by a streamlined commercial strategy and expansion from dermatology to pediatrics and pharmacy distribution.

• The business model shifted from buy-and-bill to a majority pharmacy distribution, improving access and reimbursement for clinicians and patients.

• A new Chief Commercial Officer with dermatology expertise was hired to drive further commercial growth and pediatric market penetration.

• Efforts to curb compounded cantharidin competition have been effective, with increased clinician preference for the FDA-approved, reimbursed product.

Product performance, market dynamics, and growth drivers

• YCANTH adoption is robust among dermatologists, pediatricians, and primary care, with nurses and PAs also administering treatment.

• The main competitor remains the watch-and-wait approach; a new market entrant has increased overall awareness and treatment rates.

• Access improvements, including a $25 copay for most commercially insured patients and minimal Medicaid payments, have made treatment more affordable.

• Growth is driven by clinician education, improved pharmacy access, and a shift in mindset from observation to active treatment.

Pipeline and clinical development

• The common warts program targets a market three times larger than molluscum, with two global Phase III trials underway and $40 million in funding from the Japanese partner.

• Phase III trials for common warts involve 300 patients each, with the first trial in the US and the second split between the US and Japan; enrollment is expected to complete by mid-2027.

• The goal is a broad label for common warts, with potential future expansion into genital warts based on promising Phase II data.

• European regulatory discussions are ongoing for YCANTH in molluscum, with plans to pursue common warts approval using global Phase III data.